Back to Newsroom
Back to Newsroom

Brain Tunnelgenix Technologies Opens R&D Office in Florida for Brain Temperature-Monitoring Solutions -- Company Develops, Markets And Sells Systems For Personal, Professional, Athletic, Military and Medical Use

Monday, 31 October 2016 11:45 AM

Brain Tunnelgenix Technologies

Topic:

AVENTURA, FL / ACCESSWIRE / October 31, 2016 / Brain Tunnelgenix Technologies (BTT Corp.) has opened a Research and Development office here for its proprietary brain temperature monitoring solutions. Company founder and president Dr. M. Marc Abreu leads a management team that markets, distributes and develops proprietary and worldwide, patented products.

"Aventura is an ideal location to build a customer base and create national and international collaborations," Dr. Abreu said. "We can draw from a wealth of business and technology talent and make global connections."

Dr. Abreu is a pioneer in research on body thermal energy and brain thermodynamics, having studied the subject as part of the clinical faculty at the Yale School of Medicine for more than a decade. He discovered the brain thermal tunnel, which for the first time in history enabled noninvasive, continuous measurement of human brain temperature.

BTT Corp. offers a broad range of solutions for improving health by making use of the thermophysical and bi-directional tunnel that starts at the intersection of the nose and eyebrow where thermal signature patterns are captured from the brain. With that information, their scientists and researchers are developing diagnostics and specific therapies using brain thermal modulation to help manage and treat various conditions and diseases.

The company's product line includes the FDA approved Abreu BTTTM 700 System, a computer-based system for recording brain thermal tunnel temperature continuously and noninvasively during surgery and in other health care settings; and the Abreu BTT™ Spot Thermometer, an infrared thermometer that uses the BTT spot to take core and brain temperature quickly and noninvasively. These devices render the most accurate and true core and brain temperature without the correction factors found in all other digital and infrared thermometers. The company is also working on BTT™ Smart Glasses to be worn during physical activities.

These technologies and systems have application to medical, consumer, construction, sports, military and other markets. The company's technological platform promises to set a new standard in health care while improving care in the workplace, athletic fields, battlefield, hospitals, emergency rooms, operating rooms, doctors' offices, ambulances and in the home.

The Aventura office provides excellent facilities for Dr. Abreu, an innovator, medical doctor and academician. Dr. Abreu was previously clinical faculty at Harvard Medical School. He is currently on the clinical faculty of the Department of Anesthesiology at Yale University, where he was previously a post-doctoral fellow and faculty in the Department of Ophthalmology and Visual Sciences.

ABOUT BRAIN TUNNELGENIX TECHNOLOGIES

BTT Corp. is a MedTech company that develops, manufactures and markets solutions based on the brain thermal tunnel with a broad range of applications. The company is the sole licensee of proprietary products that track brain temperature in a noninvasive way using the brain temperature tunnel. The company is also developing subscription services to help manage and research numerous health conditions, such as Alzheimer's disease, multiple sclerosis and sleep disorders. BTT Corp. is a member of Microsoft BizSpark Plus, a highly selective program for startup technology firms. The company operates research and engineering facilities in Aventura, Florida, Bridgeport, Connecticut and Sao Paulo, Brazil. For more information, visit http://www.bttcorp.com.

Media contacts:

Don Silver
Boardroom PR
[email protected]
954-370-8999 office / 954-629-7523 (cell)

Hugo H. Ottolenghi
[email protected]
561-354-6627 (office) / 561-818-2946 (cell)

SOURCE: Brain Tunnelgenix Technologies

Topic:
Back to newsroom
Back to Newsroom
Share by: